ImmuPharma (LON:IMM) issued its quarterly earnings data on Wednesday. The company reported GBX (1.69) (($0.02)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Shares of IMM stock opened at GBX 11.48 ($0.15) on Thursday. ImmuPharma has a 1 year low of GBX 6.91 ($0.09) and a 1 year high of GBX 32.29 ($0.42). The company has a debt-to-equity ratio of 0.51, a current ratio of 6.73 and a quick ratio of 3.90. The stock’s 50 day simple moving average is GBX 13.41 and its two-hundred day simple moving average is GBX 13.33. The company has a market cap of $28.26 million and a PE ratio of -2.87.
ImmuPharma Company Profile
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More: Reverse Stock Split
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.